Without acknowledging the vascular connection, the MS drug development edges into blood flow and plasma with lisinopril trials. What do they say about the current immune ablating drugs? "Just tinkering with the status quo is not working, and it's really resulted in an unsustainable clinical development model that has translated into escalating costs." No, really?


FDA clears startup's virtual trial for drug against multiple sclerosis - FierceBiotechIT
www.fiercebiotechit.com
Transparency Life Sciences picked up a win for its bet on open innovation in transforming drug development. The FDA cleared the developer's IND application to study a generic hypertension drug...